Guangdong Hybribio Biotech Co.,Ltd. (China)

Guangdong Hybribio Biotech Co., Ltd., located in Chaozhou, is a developer and supplier of nucleic acid molecular diagnostic products in China. The company focuses on the research, production, and sales of molecular diagnostic reagents and related products, as well as providing related services. In 2016, their "Human Papillomavirus Gene Typing Test Kit and Gene Chip Preparation Method (ZL200710030723.6)" won the 18th China Invention Patent Gold Award, representing advanced levels of independent innovation in HPV testing in China. On April 12, 2017, Guangdong Hybribio Biotech Co., Ltd. (300639) went public and listed on the Growth Enterprise Market. With independent innovation, Guangdong Hybribio Biotech Co., Ltd. was recognized as a high-tech enterprise in 2008 and an innovative enterprise in Guangdong Province in 2012. In the same year, they were approved by the Guangdong Provincial Department of Science and Technology, the National Development and Reform Commission, and the Economic and Information Commission to establish the "Guangdong Province Molecular Diagnostic Engineering Technology Research and Development Center for Human Papillomavirus (HPV)-Related Diseases," becoming one of the few companies in the molecular diagnostic field with the capability to build a provincial-level research and development center. In 2013, they were approved by the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee to establish a postdoctoral research workstation. In September 2015, the National Strategic Emerging Industry Development Project - Guangdong Hybribio Biotech Chip Development Industrial Base was officially launched in the Guangzhou Sino-Singapore Knowledge City, combining industry, academia, and research to form a dual-chain development model with Hybribio's unique characteristics in the field of biotechnology. In 2017, Guangdong Hybribio Biotech Co., Ltd. was recognized as a "National Intellectual Property Advantage Enterprise" and a "National Gene Testing Technology Application Demonstration Center." In 2018, they were approved by the Guangdong Provincial Department of Human Resources and Social Security to establish a Guangdong Provincial Doctoral Workstation. Guangdong Hybribio Biotech Co., Ltd. has always focused on the independent research and development of molecular diagnostic technology, actively expanding the application areas of nucleic acid molecular diagnostic technology, and continuously promoting the transformation and upgrading of nucleic acid molecular diagnostic application technology. Their proprietary hybridization technology platform, which has independent intellectual property rights, combines PCR amplification technology, molecular hybridization technology, and biochip technology, among other technological advantages, greatly improving clinical diagnostic efficiency and accuracy. Many laboratories worldwide have used Hybribio's products to participate in the World Health Organization (WHO) HPV Network Monitoring Assessment for six consecutive times, and the results fully meet the requirements of clinical application levels and laboratory capabilities. Guangdong Hybribio Biotech Co., Ltd. has long been involved in national and local government's two-cancer screening projects. They have jointly organized a three-year, 600-session national grassroots reproductive tract infection prevention and control training program with the National Health Commission and the Chinese Medical Association, providing guidance for clinical medication for grassroots doctors. Since 2011, they have jointly established the China (HPV) Database with the Medical and Health Science and Technology Development Research Center of the Ministry of Health, providing theoretical basis for cervical cancer prevention and control, vaccine development, and the formulation of cervical cancer public health policies. Building on the significant achievements in the industrialization of molecular diagnostics, the Hybribio Group has established over 30 molecular medical laboratories in Hong Kong and key cities across the country. With the brand image of "Hybribio Medical Laboratory, Nucleic Acid Diagnostic Expert," they provide advanced molecular diagnostic technology services to grassroots medical institutions nationwide, expand their business downstream in the industry chain, and realize an integrated business model of "platform + reagents + services." Since the outbreak of the COVID-19 pandemic, relying on their deep experience in the field of nucleic acid molecular diagnostics in China, Guangdong Hybribio Biotech Co., Ltd. has independently developed a series of respiratory pathogen testing products and formed a comprehensive solution for COVID-19 virus testing. They use scientific and technological strength to safeguard the lives, health, and safety of the people. Their 32 Hybribio medical laboratories nationwide have become designated COVID-19 nucleic acid testing institutions by the National Health Commission. They actively responded to the government's call and participated in large-scale COVID-19 nucleic acid testing screenings in Guangdong, Hubei, Beijing, Xinjiang, Liaoning, Hong Kong, Yunnan, Sichuan, Heilongjiang, Nanjing, Hunan, Chongqing, Henan, Shanghai, Fujian, Shaanxi, Guangxi, and other regions. In multiple nationwide screening tasks, they have built the "Puji" pneumatic laboratory and the "Kaixuan" cabin laboratory, improved local nucleic acid testing capabilities, successfully completed screening tasks, and received praise and recognition from local governments. They have also accumulated a large amount of rich experience in COVID-19 screening work in different application scenarios. As a mission-driven and responsible national brand enterprise, Guangdong Hybribio Biotech Co., Ltd. will continue to play an active role in promoting the development of the medical and health industry together with the biotechnology industry.